Exercise of options against Surgical Science’s two largest shareholders

Surgical Science has been informed that Jeff Berkley, founder of Mimic Technologies and the largest shareholder in the company when Surgical Science acquired it in January 2021, has called on 119,982 call options from Surgical Science's two main shareholders.

In January 2021, Surgical Science announced that the company had entered into an agreement to acquire Mimic Technologies, an American company with operations in robotic surgery. The sellers were approximately 10 shareholders, of which Jeff Berkley was the largest shareholder with about 40 percent of the company.

As part of the acquisition, Jeff Berkley invested in 169,800 shares in Surgical Science. These were issued at a subscription price of SEK 98.30, corresponding to the subscription price in the directed share issue that was carried out to finance the acquisition.

Surgical Science has today been informed that the company's two main owners, Jan Bengtsson and Roland Bengtsson, in connection with the acquisition, also issued 119,982 call options from their own holdings to Jeff Berkley. This means that the options do not entail any dilution for other shareholders upon exercise. The exercise price of the options was set at SEK 120.00 and the exercise period was 20 December 2023 to 20 January 2024.

Jeff Berkley has called for exercise of these options. The sale is reported by Jan Bengtsson through the company Marknadspotential AB and Roland Bengtsson through the company Semelin Kapitalförvaltning AB to the Swedish Financial Supervisory Authority.

Gothenburg, Sweden, January 15, 2024
Surgical Science Sweden AB (publ)

This press release, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

Exercise of options against Surgical Science's two largest shareholders

Exercise of options against Surgical Science's two largest shareholders